<DOC>
	<DOC>NCT02040207</DOC>
	<brief_summary>The purpose of this research study is to test the safety and local tolerance of repeated treatment with AM-101.</brief_summary>
	<brief_title>AM-101 in the Treatment of Post-Acute Tinnitus 2</brief_title>
	<detailed_description>This open-label extension study is assessing the safety and local tolerance of repeated treatment with AM-101 in subjects previously treated in the scope of the TACTT3 study.</detailed_description>
	<mesh_term>Tinnitus</mesh_term>
	<criteria>Completion of TACTT3 study; Negative pregnancy test (woman of childbearing potential); Willing and able to attend the study visits. Other protocoldefined inclusion criteria may apply. Adverse event leading to treatment discontinuation in TACTT3; Meniere's Disease, endolymphatic hydrops, acoustic neuroma, severe or fluctuating hearing loss, otitis media, otitis externa, abnormality of tympanic membrane; Ongoing drugbased therapy for otitis media or otitis externa; Drugbased therapy known as potentially tinnitusinducing; Other treatment of tinnitus; Drug abuse or alcoholism; Subjects with psychiatric diseases requiring drug treatment; Use of antidepressant or antianxiety medication; Any clinically relevant disorder or abnormality in physical examination; Women who are breastfeeding, pregnant or who are planning to become pregnant during the study; Women of childbearing potential who are unwilling or unable to practice contraception. Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>76 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>